BD PharmingenTM FITC Active Caspase-3 Apoptosis Kit

Description

Flow cytometric analysis of apoptotic and non-apoptotic populations for active caspase-3. Jurkat cells Human T-cell leukemia; ATCC TIB-152 were left untreated left panel or treated for 4 hr with camptothecin right panel to induce apoptosis. Cells were permeabilized, fixed, and stained for active caspase-3 as described in the accompanying Staining Protocol. Cells were then analyzed by flow cytometry. Untreated cells were primarily negative for the presence of active caspase-3, whereas greater than one third of the treated cells were positive for active caspase-3 staining right panel, M2 . Flow cytometric analysis of apoptotic and non-apoptotic populations for active caspase-3. Jurkat cells Human T-cell leukemia; ATCC TIB-152 were left untreated left panel or treated for 4 hr with camptothecin right panel to induce apoptosis. Cells were permeabilized, fixed, and stained for active caspase-3 as described in the accompanying Staining Protocol. Cells were then analyzed by flow cytometry. Untreated cells were primarily negative for the presence of active caspase-3, whereas greater than one third of the treated cells were positive for active caspase-3 staining right panel, M2 . Show More Flow cytometric analysis of apoptotic and non-apoptotic populations for active caspase-3. Jurkat cells Human T-cell leukemia; ATCC TIB-152 were left untreated left panel or treated for 4 hr with camptothecin right panel to induce apoptosis. Cells were permeabilized, fixed, and stained for active caspase-3 as described in the accompanying Staining Protocol. Cells were then analyzed by flow cytometry. Untreated cells were primarily negative for the presence of active caspase-3, whereas greater than one third of the treated cells were positive for active caspase-3 staining right panel, M2 .